NONPROFIT, NONPARTISAN PLATFORM OF ACCURATE SCIENCE-BASED SOLUTIONS TO COVID-19

Hookipa Biotech best-in-class active immunization therapies for infectious diseases and oncology

Hookipa Biotech AG is a clinical stage biotech company aiming to develop best-in-class active immunization therapies for infectious diseases and oncology.   The company's proprietary TheraT® and Vaxwave® platforms have shown promising abilities to elicit high neutralizing antibody responses, but also necessary levels of T cell responses, currently missing in most vaccine and therapeutic approaches. Hookipa’s vectors are not impeded by vector-neutralizing antibodies and can be administered repeatedly, providing even greater immune protection. Levels of specific T cells generated by TheraT® are unprecedented in the field and have the potential to transform active immune-therapy in cancers. In upcoming news, Hookipa Biotech is presenting at the NYC Oncology Investor Conference, occurring on May 8-9 at the office of Wilson Sonsini in New York City.  Learn more and register to attend the conference at www.nyconcologyconference.com.

To continue reading, please Login or Join